Literature DB >> 1537837

Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins.

M Anafi1, A Gazit, C Gilon, Y Ben-Neriah, A Levitzki.   

Abstract

The transforming abl proteins p160gag-abl, p185bcr-abl, and p210bcr-abl and the normal protein p140c-abl have identical catalytic sites, but differ in their N-terminal domains. Previous studies have indicated that the transforming abl proteins possess higher tyrosine kinase activity than the normal abl proto-oncogene product. In the present study, we demonstrate that two transforming abl proteins, p210bcr-abl and p160gag-abl, exhibit a higher affinity toward ATP and synthetic tyrosine containing substrates than p140c-abl. Furthermore, protein tyrosine kinase blockers from the tyrphostin family can discriminate between normal abl and transforming abl proteins of both human and mouse origin. These results suggest that the transforming potency of the abl proteins may result from their higher affinities toward intracellular signal transducers and demonstrate for the first time that oncogene products can differ from their homologous proto-oncogene product in substrate specificity. The ability of tyrphostins to discriminate between normal and transforming abl proteins suggests that it may be possible to design specific abl kinase inhibitors to combat abl-associated human leukemias.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537837

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Label-free detection of small-molecule-protein interactions by using nanowire nanosensors.

Authors:  Wayne U Wang; Chuo Chen; Keng-hui Lin; Ying Fang; Charles M Lieber
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  p140/c-Abl that binds DNA is preferentially phosphorylated at tyrosine residues.

Authors:  R Dikstein; R Agami; D Heffetz; Y Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 4.  Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.

Authors:  Jorge Cortes; Andreas Hochhaus; Timothy Hughes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

Review 5.  Development of an effective therapy for chronic myelogenous leukemia.

Authors:  David W Woessner; Carol S Lim; Michael W Deininger
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

6.  My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.

Authors:  Alexander Levitzki; Shoshana Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

Review 7.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

8.  Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.

Authors:  David W Woessner; Carol S Lim
Journal:  Mol Pharm       Date:  2012-12-18       Impact factor: 4.939

9.  The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity.

Authors:  Michael Welsh; Charlotte Welsh; Maria Ekman; Johan Dixelius; Robert Hägerkvist; Cecilia Annerén; Björn Akerblom; Siavosh Mahboobi; Subhashini Chandrasekharan; Edison T Liu
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

10.  Tyrphostin inhibition of ATP-stimulated DNA synthesis, cell proliferation and fos-protein expression in vascular smooth muscle cells.

Authors:  D Erlinge; M Heilig; L Edvinsson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.